Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.31 |
| ▸ | MAP3K4 | Q9Y6R4 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17532290 | 0.92 | PYGL (0.33) | MAPK14MAPK11DDR1DDR2ABL1 | |
| SCHEMBL22167480 | 0.91 | S1PR1 (0.36) | MAPK14MAPK11DDR1DDR2PYGL | |
| SCHEMBL17532289 | 0.91 | S1PR4 (0.35) | MAPK14MAPK11DDR1DDR2ABL1 | |
| SCHEMBL17532291 | 0.91 | S1PR1 (0.36) | MAPK14MAPK11DDR1DDR2PYGL | |
| SCHEMBL17532298 | 0.91 | PYGL (0.33) | MAPK14MAPK11CTSLCTSSDDR1 | |
| SCHEMBL22167228 | 0.91 | S1PR4 (0.35) | MAPK14MAPK11DDR1DDR2ABL1 | |
| SCHEMBL22167389 | 0.91 | MAPK14 (0.35) | MAPK14MAPK11CTSLCTSSDDR1 | |
| SCHEMBL22167489 | 0.91 | S1PR4 (0.36) | MAPK14MAPK11DDR1DDR2PYGL | |
| SCHEMBL17492911 | 0.91 | S1PR4 (0.36) | MAPK14MAPK11DDR1DDR2PYGL | |
| SCHEMBL19181503 | 0.91 | S1PR4 (0.36) | MAPK14MAPK11DDR1DDR2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ACE2 4098/4885MAPK14 1911/4885MAPK11 1766/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ACE2 4098/4885MAPK14 1911/4885MAPK11 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.